Form 4: Sarepta Therapeutics Executive Dallan Murray Reports Stock Transactions

Chief Customer Officer Dallan Murray of Sarepta Therapeutics reports the vesting of performance stock units and subsequent stock sales to cover tax obligations.

Summary

• Dallan Murray, Chief Customer Officer of Sarepta Therapeutics, reported transactions involving the company's stock.
• On March 6, 2025, 17,500 shares vested under a performance stock unit (PSU) award granted on March 6, 2023.
• On March 7, 2025, 549 shares were sold at $103.7 to cover tax obligations related to restricted stock units vesting.
• Additionally, 8,613 shares were sold at $103.7 to cover tax obligations related to the vesting of the PSUs.
• Following these transactions, Murray directly owns 28,159 shares of Sarepta Therapeutics.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock transactions, so the sentiment is neutral.

Industry Context

Executive stock transactions are a routine part of corporate governance and are closely watched by investors for insights into management's perspective on the company's performance and future prospects. Form 4 filings are a standard requirement by the SEC.

Stakeholder Impact

• The stock sales could have a minor impact on the stock price, but are primarily driven by tax obligations.

Key Dates